MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • Noticias
  • Store
  • Corredores
  • Descargar
  • Calendario económico
  • Señales Comerciales
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
Axsome Therapeutics, Inc

AXSM

#863
Axsome Therapeutics, Inc
163.8900
+1.83%
Sector:
Básica:
Profit Currency:
Rango diario
163.8900
163.8900
Rango anual
123.5000
191.5000
Cambio diario
+1.83%
Monthly Change
-12.68%
6 month change
+25.88%
Cambio anual
+25.88%
Cierres anteriores
160.9500
Open
163.8900
Bid
Ask
Low
163.8900
High
163.8900
Volumen
137
  1. Markets
  2. Acciones
  3. Atención Sanitaria
  4. AXSM
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Noticias

Investor's Business Daily Investor's Business Daily
NVDA NVO SNOW CRM WDAY
vorgestern, 16:04
Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review
Investor's Business Daily Investor's Business Daily
ROAD FNV AEM EQX TARS
2026.02.24
Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders
Zacks Zacks
JAZZ AXSM CSTL HRMY
2026.02.24
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Investing Investing
AXSM
2026.02.24
Axsome Therapeutics: UBS hebt Kursziel wegen Vertriebsexpansion an
Investing Investing
AXSM
2026.02.24
UBS raises Axsome Therapeutics stock price target on sales force expansion
Investing Investing
AXSM
2026.02.24
Wolfe Research nimmt Bewertung für Axsome mit "Outperform" auf/n
Investing Investing
AXSM
2026.02.24
Wolfe Research initiates Axsome stock with outperform rating
Investing Investing
AXSM
2026.02.24
RBC Capital erhöht Kursziel für Axsome Therapeutics nach Quartalszahlen
Investing Investing
AXSM
2026.02.24
RBC Capital raises Axsome Therapeutics price target on earnings
Investing Investing
AXSM
2026.02.24
Axsome startet Phase-3-Studie mit Solriamfetol zur Behandlung von Depressionen
Investing Investing
AXSM
2026.02.24
Axsome doses first patient in depression trial with solriamfetol
Investing Investing
AXSM
2026.02.24
Guggenheim hebt Kursziel für Axsome wegen starker Absatzzahlen auf 220 US-Dollar an

Markets

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Charts & Ideas

  • Ideas comerciales
  • Ideas ilustrativas
  • Gráfico

MQL5 Community

  • Market
  • Señales
  • Foro
  • Artículos
  • CodeBase

Noticias

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Corredores

  • Todos los brókeres
  • Fórex
  • Acciones
  • Metales
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Información y contacto Legal
Copyright 2000-2026, MetaQuotes Ltd